Team ADHD

Don’t have time to map out overlapping symptoms?

Unmasking ADHD

Then don't miss out on this exclusive resource "Unmasking ADHD"

A simple tool to help you differentiate between ADHD and the most common overlapping comorbidities in children

Enter your full name and email and you will receive your complimentary download today

ADHD Definitely Has Diagnostic ComplexitiesADHD Definitely Has Diagnostic Complexities
ADHD Often Details His DayADHD Often Details His Day
ADHD… Moods… What's Causing Her Disposition?ADHD… Moods… What's Causing Her Disposition?
Team ADHD

Growing evidence support a paradigm of ADHD as a complex disorder, with neurobiologic vulnerabilities, and various associated comorbidities.1,7-9

Andrew J Cutler, MD
Birgit Amann, MD
Rakesh Jain, MD, MPH
Frank A Lopez, MD
Ann Childress, MD
Greg Mattingly, MD
Michelle Voegels, PMHNP-BC
Vladimir Maletic, MD, MS
Theresa Cerulli, MD

Introducing TEAM ADHD:
Your Professional Allies in the Treatment of ADHD

TEAM ADHD* is a group of psychiatric healthcare professionals united by an expertise in the field of ADHD treatment.

Introducing TEAM ADHD: Your Professional Allies in the Treatment of ADHD

TEAM ADHD* are a group of psychiatric healthcare professionals united by an expertise in the field of ADHD treatment.

Andrew J Cutler, MD
Rakesh Jain, MD, MPH
Ann Childress, MD
Greg Mattingly, MD
Vladimir Maletic, MD, MS
Michelle Voegels, PMHNP-BC
Frank A Lopez, MD
Birgit Amann, MD
Theresa Cerulli, MD

*TEAM ADHD is consultants for Supernus Pharmaceuticals and have been compensated for their time.

Psychiatric comorbidities are often linked to ADHD

In addition to core features (inattention, hyperactivity, and impulsivity), children with ADHD frequently experience other psychiatric symptoms that can diminish their quality of life.1

Join Team ADHD Today

A simple tool to help you differentiate between ADHD and the most common overlapping comorbidities in children, receive your complimentary download today.

“ADHD is too important to ignore.”10

-Greg Mattingly, MD

More to ADHD

Visit our patient site for resources designed for parents of children and adolescents with ADHD.

Visit MoreToADHD.com

References: 1. Banaschewski T, Becker K, Dopfner M, Holtmann M, Rosler M, Romanos M. Attention deficit/hyperactivity disorder. Dtsch Arztebl Int. 2017;114(9):149-159. 2. Hervas A, de Santos T, Quintero J, et al. Delphi consensus on attention deficit hyperactivity disorder (ADHD): evaluation by a panel of experts. Actas Esp Psiquiatr. 2016;44(6):231–243. 3. Reale L, Bartoli B, Cartabia M, et al. Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2017;26(12):1443–1457. 4. Clemow DB, Bushe C, Mancini M, et al. Neuropsychiatr Dis Treat. 2017;13:357-371. 5. Di Trani M, Di Roma F, Andriola E, et al. Psychiatry Investig. 2014;11(2):137-142. 6. Chang Z, D’Onofrio BM, Quinn PD, Lichtenstein P, Larsson H. Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study.. Biol Psychiatry. 2016;80(12):916-922. 7. Koolwijk I, Stein DS, Chan E, Powell C, Driscoll K, Barbaresi WJ. “Complex” attention-deficit hyperactivity disorder, more norm than exception? Diagnoses and comorbidities in a developmental clinic. J Dev Behav Pediatr. 2014;35:591-597. 8. Brown TE. Developmental complexities of attentional disorders. In: Brown TE, Ed. ADHD Comorbidities: Handbook for ADHD Complications in Children and Adults; Arlington, VA: American Psychiatric Publishing Inc; 2009:3-23. 9. Shaw P, Polanczyk GV. Combining epidemiological and neurobiological perspectives to characterize the lifetime trajectories of ADHD. Eur Child Adolesc Psychiatry. 2017;26(2):139-141. 10. Data on file. Supernus Pharmaceuticals.